Earnings Releases·Oct 29, 2026, 4:12 PM ET

Immuneering — Third Quarter 2026 Earnings Summary

Cash and marketable securities decreased to $166.1 million as of September 30, 2026, from $217.0 million at year-end 2025, while the updated cash runway now extends operations into the fourth quarter of 2028.
R&D expenses rose to $20.7 million for the quarter from $10.9 million in the prior year period, driven by higher clinical costs and personnel, contributing to a net loss of $24.2 million ($0.37 per share) versus $15.0 million ($0.38 per share) previously.
Phase 3 MAPKeeper 301 trial enrollment targets were expanded from 510 to 570 patients with enrollment ahead of schedule, potentially accelerating the mid-2028 topline data readout.
Topline data for the Phase 2 atebimetinib + mGnP pancreatic cancer trial is expected in the first half of 2027, with a Phase 2 lung cancer readout anticipated in late 2027 and IND-enabling studies for the next DCI program starting mid-2027.
Management highlighted strong trial momentum and unprecedented survival data (17.3-month median overall survival) reported at ASCO, noting the Phase 2 pancreatic trial follow-up was extended due to patients living longer than projected.